Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21

European Journal of Haematology
Hareth NahiNiels Abildgaard

Abstract

Chromosomal aberrations have significant prognostic importance in multiple myeloma (MM). However, proteasome inhibitors (PI) and IMiDs may partly overcome the poor prognostic impact of some of them. In this study, we investigated a population-based consecutive cohort newly diagnosed patients with MM admitted during a defined time period to hospitals in Denmark, Norway, and Sweden. The impact of treatment modality on the prognostic importance of specific chromosomal aberration was investigated, with special reference to gain 1q21. The median follow-up of patients still alive at analysis was 40 months for the high-dose (HDT)-treated ones and 29 months for the whole population. Three hundred forty-seven patients with a known 1q21 status were included in this study. The 347 patients were divided into three groups, that is, 119 patients with the 1q21 gain, 105 patients with other aberrations (OA), that is, del(13q), del(17p), t(4,14), and/or (14;16), and 123 patients with no aberrations (NA). The groups were compared in terms of overall survival (OS), time to progression (TTP), and response. The 3-yr OS for patients with gain 1q21 was 60% compared to patients with OA 74% and NO 82% (gain 1q21 vs. NO P < 0.001; gain 1q21 vs. OA P = 0...Continue Reading

References

Jul 1, 1995·Cancer Genetics and Cytogenetics·J R SawyerB Barlogie
Jun 27, 2007·British Journal of Haematology·Bart BarlogieJohn D Shaughnessy
Dec 12, 2007·Best Practice & Research. Clinical Haematology·S Vincent Rajkumar, Francis Buadi
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Nov 20, 2008·British Journal of Haematology·T SutluH Nahi
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cyrille HulinPhilippe Moreau
May 8, 2010·Blood·Anders WaageUNKNOWN Nordic Myeloma Study Group
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre WijermansUNKNOWN Dutch-Belgium Cooperative Group HOVON
Jul 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hervé Avet-LoiseauJean-Luc Harousseau
Mar 1, 2012·Haematologica·Fiona M RossUNKNOWN European Myeloma Network
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hervé Avet-LoiseauPhilippe Moreau
Mar 14, 2013·Blood·Gösta GahrtonUNKNOWN EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee
Aug 27, 2013·Leukemia·W J ChngUNKNOWN International Myeloma Working Group

❮ Previous
Next ❯

Citations

Oct 30, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Fabian BockMuzaffar H Qazilbash
Mar 11, 2017·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Adrian A Carballo-ZarateXinyan Lu
Apr 5, 2020·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Bruna FerreiraCristina João
May 1, 2021·Blood Cancer Journal·Timothy M SchmidtSaad Z Usmani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.